Related Experiment Videos
Oral GPIIb/IIIa antagonists: what went wrong?
1Department of Clinical Pharmacology, School of Pharmacy, Royal College of Surgeons, St Stephens Green, Dublin, Ireland. dcox@rcsi.ie
Current Pharmaceutical Design
|May 12, 2004
Summary
Oral GPIIb/IIIa antagonists failed in trials due to issues like low bioavailability and partial agonism. Addressing these challenges could enable a new generation of effective oral inhibitors for preventing thrombotic events.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Drug Development
Background:
- Glycoprotein (GP) IIb/IIIa receptor antagonists are potent platelet aggregation inhibitors.
- Intravenous formulations are effective in acute coronary syndromes and percutaneous coronary intervention.
- Oral GPIIb/IIIa antagonists have shown limited efficacy and increased mortality in clinical trials.
Purpose of the Study:
- To analyze the reasons behind the failure of oral GPIIb/IIIa antagonists.
- To identify key challenges hindering the development of effective oral GPIIb/IIIa antagonists.
- To propose strategies for developing a new generation of oral GPIIb/IIIa antagonists.
Main Methods:
- Review of clinical trial data for oral and intravenous GPIIb/IIIa antagonists.
- Analysis of pharmacokinetic and pharmacodynamic properties of oral GPIIb/IIIa antagonists.
- Investigation of mechanisms contributing to oral GPIIb/IIIa antagonist failure, including partial agonism and pharmacogenomics.
Main Results:
- Oral GPIIb/IIIa antagonists demonstrated no benefit or increased mortality compared to placebo.
- Key issues identified include different treatment targets (acute vs. chronic), suboptimal dosing, low bioavailability, and significant peak-trough differences.
- Partial agonism and drug-induced conformational changes in GPIIb/IIIa, alongside pharmacogenomic factors like Pl(A) polymorphism, contribute to treatment failure.
Conclusions:
- The failure of oral GPIIb/IIIa antagonists is multifactorial, stemming from pharmacokinetic limitations and drug-specific mechanisms.
- Addressing issues such as bioavailability, peak-trough variability, partial agonism, and pharmacogenomic influences is crucial.
- Developing a new generation of oral GPIIb/IIIa antagonists requires a targeted approach to overcome these identified challenges for improved thrombotic event prevention.